| Name | Methyl pyropheophorbide-a |
| Description | Methyl pyropheophorbide-a (MPPa) is a chlorine photosensitizer and a derivative of chlorophyll a. It is photodynamically active, induces apoptosis and inhibits tumor growth, and can be used in photodynamic therapy (PDT) of cancer. |
| In vitro | In PC-3M cells, after treatment with Methyl pyropheophorbide-a (2 μM; 12 h) under LC75 conditions (2 μM + 55.6 kJ/m²), the apoptosis rates were approximately 0.27%, 6.15%, 20.49%, 50.76%, 65.39%, 64.92%, and 64.37% at 1, 3, 6, 12, 18, and 24 hours post-treatment, respectively[1]. |
| In vivo | In male BALB/c nude mice (6-8 weeks old, 16-20 g) bearing PC-3M tumors, Methyl pyropheophorbide-a (15 mg/kg; tail vein injection and topical injection) resulted in tumor volume and weight inhibition rates of 46.78% and 41.84% in the tail vein injection group, respectively, and 78.66% and 72.07% in the topical injection group, respectively[2]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 1 mg/mL (1.82 mM), Sonication is recommended.
|
| Keywords | MPPa (Methyl pyropheophorbide-a) | Methyl pyropheophorbide-a | Methyl pyropheophorbidea | Methyl pyropheophorbide a | Apoptosis |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Acetylcysteine | L-Glutamic acid monosodium salt monohydrate | Sodium 4-phenylbutyrate | L-Ascorbic acid | Metronidazole | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
United States
